Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy

References

• Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4:a015354. doi:10.1101/cshperspect.a015354
   PubMed Web of Science ®Google Scholar
• Prignano F, Rogai V, Cavallucci E, Bitossi A, Hammen V, Cantini F. Epidemiology of psoriasis and psoriatic arthritis in Italy-A systematic review. Curr Rheumatol Rep. 2018;20:43. doi:10.1007/s11926-018-0753-1
   PubMed Web of Science ®Google Scholar
• Saraceno R, Mannheimer R, Chimenti S. Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol. 2008;22:324–329.
   PubMed Web of Science ®Google Scholar
• Valent F, Tullio A, Errichetti E, Stinco G. The epidemiology of psoriasis in an Italian area: population-based analysis of administrative data. G Ital Dermatol Venereol. 2020;155:652–657. doi:10.23736/S0392-0488.18.06020-0
   Web of Science ®Google Scholar
• Vena GA, Altomare G, Ayala F, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol. 2010;20:593–598.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Jo SJ, Naldi L, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179:173–181. doi:10.1111/bjd.16332
   PubMed Web of Science ®Google Scholar
• Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:1475. doi:10.3390/ijms20061475
   PubMed Web of Science ®Google Scholar
• Radi G, Campanati A, Diotallevi F, Bianchelli T, Offidani A. Novel therapeutic approaches and targets for treatment of psoriasis. Curr Pharm Biotechnol. 2021;22:7–31. doi:10.2174/1389201021666200629150231
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32:1507–1514.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177:1033–1042. doi:10.1111/bjd.15706
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76:60–69 e69. doi:10.1016/j.jaad.2016.08.008
   PubMed Web of Science ®Google Scholar
• Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21:111. doi:10.1186/s13075-019-1882-2
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two Phase 3 trials. N Engl J Med. 2014;371:326–338. doi:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27–36 e21. doi:10.1016/j.jaad.2015.04.011
   PubMed Web of Science ®Google Scholar
• Bagel J, Blauvelt A, Nia J, et al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol. 2020;35:135–142. doi:10.1111/jdv.16558
   Web of Science ®Google Scholar
• European Medicines Agency. Cosentyx (secukinumab). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx. Accessed October 7, 2020.
   Google Scholar
• Novartis. COSENTYX® (secukinumab) for injection, for subcutaneous use: US prescribing information; 2020. Available from: https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf. Accessed October 7, 2020.
   Google Scholar
• Brixner D, Mittal M, Rubin DT, et al. Participation in an innovative patient support program reduces prescription abandonment for Adalimumab-treated patients in a commercial population. Patient Prefer Adherence. 2019;13:1545–1556. doi:10.2147/PPA.S215037
   PubMed Web of Science ®Google Scholar
• Brixner D, Rubin DT, Mease P, et al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J Manag Care Spec Pharm. 2019;25:770–779.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2017;23:859–867.
   PubMedGoogle Scholar
• Georgakopoulos JR, Ighani A, Phung M, Yeung J. Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study. J Am Acad Dermatol. 2018;78:1019–1020. doi:10.1016/j.jaad.2017.11.036
   PubMed Web of Science ®Google Scholar
• Torres T, Balato A, Conrad C, et al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81:273–275. doi:10.1016/j.jaad.2019.02.031
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of Adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183:294–302. doi:10.1111/bjd.18981
   PubMed Web of Science ®Google Scholar
• Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016;10:711–725.
   PubMed Web of Science ®Google Scholar